Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2018 07:00 ET | Source: Shire Pharmaceuticals Group

Shire plc : Xiidra® Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease

Xiidra®* (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease Canada approval represents Shire's first international market...
January 02, 2018 08:00 ET | Source: Shire Pharmaceuticals Group

Shire plc : Total voting rights

Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and...
January 02, 2018 05:01 ET | Source: Shire Pharmaceuticals Group

Shire plc : Director Declaration

Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed...
December 27, 2017 07:00 ET | Source: Shire Pharmaceuticals Group

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP,...
December 20, 2017 07:31 ET | Source: Shire Pharmaceuticals Group

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person...
December 19, 2017 07:30 ET | Source: Shire Pharmaceuticals Group

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A First and only FDA-cleared PK dosing software to support...
December 19, 2017 07:01 ET | Source: Shire Pharmaceuticals Group

Shire plc : Director Declaration

Director Declaration December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Bill Burns, Senior Independent Director of the Company, was appointed Vice-Chairman...
December 19, 2017 07:01 ET | Source: Shire Pharmaceuticals Group

Shire Announces Top-Line Results for Phase II/III Clinical Trial in Children with Hunter Syndrome and Cognitive Impairment

Shire Announces Top-Line Results for Phase II/III Clinical Trial in Children with Hunter Syndrome and Cognitive Impairment Cambridge, Ma. - December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG),...
December 14, 2017 07:00 ET | Source: Shire Pharmaceuticals Group

Shire plc : Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients through Innovative Personalized Treatment

Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients through Innovative Personalized Treatment Cambridge, MA - December 14, 2017 - Shire plc...
December 13, 2017 02:26 ET | Source: Shire Pharmaceuticals Group

Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) Freeze-dried, or lyophilized, formulation aims to...